“The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17.”, Arch Ophthalmol, vol. 123, no. 11, pp. 1484-98, 2005.
, “EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Home Study, Report Number 3.”, Retina, vol. 36, no. 8, pp. 1542-7, 2016.
, “Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4.”, Ophthalmol Retina, vol. 3, no. 4, pp. 326-335, 2019.
, “National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10.”, Arch Ophthalmol, vol. 121, no. 2, pp. 211-7, 2003.
, “Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.”, Arch Ophthalmol, vol. 121, no. 11, pp. 1621-4, 2003.
, “Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study.”, Ophthalmology, vol. 121, no. 2, pp. 535-44, 2014.
, “Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design - HOME Study report number 1.”, Contemp Clin Trials, vol. 37, no. 2, pp. 294-300, 2014.
, “Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25.”, Ophthalmology, vol. 116, no. 2, pp. 297-303, 2009.
, “Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.”, JAMA Ophthalmol, vol. 132, no. 2, pp. 142-9, 2014.
, “A simplified severity scale for age-related macular degeneration: AREDS Report No. 18.”, Arch Ophthalmol, vol. 123, no. 11, pp. 1570-4, 2005.
, “Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5.”, Ophthalmology, vol. 121, no. 6, pp. 1229-36, 2014.
,